Medical technology company Phase Holographic Imaging (PHI) announced on Tuesday that it is advancing its next-generation live cell imaging system to the final development stage.

The new HoloMonitor CellSync model is undergoing pre-production testing at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine. This system represents the first in a series aimed at establishing a new standard in automated quality control for cell and gene therapy manufacturing. Future models will integrate cutting-edge image processing and artificial intelligence technologies.

Manufactured according to ISO 9001 standards, the HoloMonitor CellSync enhances PHI's imaging technology with a new camera module and improved automated cell segmentation. These advancements have been refined over the past two years. The HoloMonitor CellSync is slated for release in the second half of 2025.